CN110234763A - 针对hbv cccdna的寡核苷酸靶向策略 - Google Patents

针对hbv cccdna的寡核苷酸靶向策略 Download PDF

Info

Publication number
CN110234763A
CN110234763A CN201780083173.6A CN201780083173A CN110234763A CN 110234763 A CN110234763 A CN 110234763A CN 201780083173 A CN201780083173 A CN 201780083173A CN 110234763 A CN110234763 A CN 110234763A
Authority
CN
China
Prior art keywords
oligonucleotides
hbv
nucleotide
oligonucleotide
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
CN201780083173.6A
Other languages
English (en)
Chinese (zh)
Inventor
S.格利亚兹诺夫
M.菲茨杰拉德
A.D.斯托里舍娃
J.洪
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jansen Biopharmaceutical Co Ltd
Original Assignee
Jansen Biopharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jansen Biopharmaceutical Co Ltd filed Critical Jansen Biopharmaceutical Co Ltd
Publication of CN110234763A publication Critical patent/CN110234763A/zh
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/314—Phosphoramidates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/334—Modified C
    • C12N2310/3341—5-Methylcytosine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201780083173.6A 2016-11-11 2017-11-13 针对hbv cccdna的寡核苷酸靶向策略 Withdrawn CN110234763A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662420801P 2016-11-11 2016-11-11
US62/420801 2016-11-11
US201762558770P 2017-09-14 2017-09-14
US62/558770 2017-09-14
PCT/US2017/061348 WO2018089914A1 (en) 2016-11-11 2017-11-13 Oligonucleotide targeting strategy for hbv cccdna

Publications (1)

Publication Number Publication Date
CN110234763A true CN110234763A (zh) 2019-09-13

Family

ID=60452809

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780083173.6A Withdrawn CN110234763A (zh) 2016-11-11 2017-11-13 针对hbv cccdna的寡核苷酸靶向策略

Country Status (10)

Country Link
US (1) US20180179542A1 (https=)
EP (1) EP3538654A1 (https=)
JP (1) JP2019533472A (https=)
KR (1) KR20190076050A (https=)
CN (1) CN110234763A (https=)
AU (1) AU2017356221A1 (https=)
CA (1) CA3043637A1 (https=)
IL (1) IL266525A (https=)
TW (1) TW201831684A (https=)
WO (1) WO2018089914A1 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113493855A (zh) * 2020-03-19 2021-10-12 首都医科大学附属北京佑安医院 一种基于RAA-CRISPR-cas13a检测HBV cccDNA的试剂盒
WO2025039916A1 (zh) * 2023-08-22 2025-02-27 浙江柏拉阿图医药科技有限公司 双-Gap修饰寡核苷酸及其在抗乙型肝炎和丁型肝炎病毒中的应用

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3682007A2 (en) * 2017-09-14 2020-07-22 Janssen BioPharma, Inc. Galnac derivatives
KR102273071B1 (ko) * 2018-06-12 2021-07-05 주식회사 에이엠사이언스 B형 간염 예방 또는 치료용 조성물
WO2019240504A1 (en) * 2018-06-12 2019-12-19 Am Sciences Co., Ltd. Modified oligonucleotides for inhibition of target gene expression
CN114829599A (zh) * 2019-12-19 2022-07-29 豪夫迈·罗氏有限公司 Scamp3抑制剂用于治疗乙型肝炎病毒感染的用途
CN115516091A (zh) * 2019-12-19 2022-12-23 豪夫迈·罗氏有限公司 Cops3抑制剂用于治疗乙型肝炎病毒感染的用途
CA3187388A1 (en) * 2020-07-27 2022-02-03 Jin Hong Hbv binding oligonucleotides and methods of use
JP2023538630A (ja) * 2020-08-21 2023-09-08 エフ． ホフマン－ラ ロシュ アーゲー Ｂ型肝炎ウイルス感染症を処置するためのａ１ｃｆ阻害剤の使用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69834038D1 (de) 1997-07-01 2006-05-18 Isis Pharmaceutical Inc Zusammensetzungen und verfahren zur verabreichung von oligonukleotiden über die speiseröhre
AR028149A1 (es) * 1999-07-08 2003-04-30 Innogenetics Nv Deteccion de la resistencia a los farmacos contra la hepatitis b
CN1317291C (zh) * 1999-09-10 2007-05-23 杰龙公司 寡核苷酸n3′→p5′硫代氨基磷酸酯,其合成及应用
EP2316942B1 (en) * 2004-12-22 2021-04-21 Alnylam Pharmaceuticals, Inc. Conserved hbv and hcv sequences useful for gene silencing
PH12019502377A1 (en) * 2011-04-21 2022-11-14 Isis Pharmaceuticals Inc Modulation of hepatitis b virus (hbv) expression
DK2991656T3 (da) * 2013-05-01 2020-03-23 Ionis Pharmaceuticals Inc Sammensætninger og fremgangsmåder til modulering af apolipoprotein c-iii-ekspression
TWI710633B (zh) * 2014-11-10 2020-11-21 美商阿尼拉製藥公司 Ｂ型肝炎病毒（ＨＢＶ）ｉＲＮＡ組成物及其用途方法
CN107683336A (zh) * 2015-05-06 2018-02-09 贝尼泰克生物制药有限公司 用于治疗乙型肝炎病毒(hbv)感染的试剂及其用途

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113493855A (zh) * 2020-03-19 2021-10-12 首都医科大学附属北京佑安医院 一种基于RAA-CRISPR-cas13a检测HBV cccDNA的试剂盒
CN113493855B (zh) * 2020-03-19 2023-12-26 首都医科大学附属北京佑安医院 一种基于RAA-CRISPR-cas13a检测HBV cccDNA的试剂盒
WO2025039916A1 (zh) * 2023-08-22 2025-02-27 浙江柏拉阿图医药科技有限公司 双-Gap修饰寡核苷酸及其在抗乙型肝炎和丁型肝炎病毒中的应用

Also Published As

Publication number Publication date
KR20190076050A (ko) 2019-07-01
AU2017356221A1 (en) 2019-05-30
WO2018089914A1 (en) 2018-05-17
US20180179542A1 (en) 2018-06-28
IL266525A (en) 2019-07-31
EP3538654A1 (en) 2019-09-18
CA3043637A1 (en) 2018-05-17
TW201831684A (zh) 2018-09-01
JP2019533472A (ja) 2019-11-21

Similar Documents

Publication Publication Date Title
CN110234763A (zh) 针对hbv cccdna的寡核苷酸靶向策略
CN109843902B (zh) 用于B型肝炎病毒感染的RNAi剂
JP6922030B2 (ja) Ｂ型肝炎およびｄ型肝炎ウイルス感染の治療のための方法
JP5892938B2 (ja) Ｈｂｖアンチセンス阻害剤
JP6270846B2 (ja) Ｂ型肝炎感染及びｄ型肝炎感染の治療方法
WO2016044182A1 (en) Solid forms of a toll-like receptor modulator
CN113507920A (zh) 用于乙型肝炎病毒感染的RNAi剂
AU2014205544B2 (en) Immune regulatory oligonucleotide (IRO) compounds to modulate toll-like receptor based immune response
CN114507663A (zh) 寡核苷酸及其在抗乙型肝炎和丁型肝炎病毒中的应用
TW202221122A (zh) Ｂ型肝炎患者之寡核苷酸治療
WO2023093896A1 (zh) 用于抑制乙型肝炎病毒(hbv)蛋白表达的组合物和方法
WO2026026776A1 (zh) 抑制APP基因表达的siRNA及其缀合物和应用
HK40014091A (en) Oligonucleotide targeting strategy for hbv cccdna
CN114057816B (zh) 富含腺嘌呤硫代磷酸酯化寡核苷酸及其抗肝炎病毒的应用
HK40065449A (en) Methods for the treatment of hepatitis b and hepatitis d virus infections
HK40097454A (zh) 用於b型肝炎病毒感染的rnai剂
HK40062579A (en) Rnai agents for hepatitis b virus infection
HK40009627B (en) Rnai agents for hepatitis b virus infection

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40014091

Country of ref document: HK

WW01 Invention patent application withdrawn after publication

Application publication date: 20190913

WW01 Invention patent application withdrawn after publication